Compounded GLP-1 in 2026: What Changed After the Shortage Ended

The FDA removed semaglutide and tirzepatide from the shortage list. Compounding didn't stop — but the rules changed. Here's what matters now.

If you've been following the compounded GLP-1 space, you've seen the headlines: shortage over, compounding crackdown, providers shutting down. The reality is more nuanced than the headlines suggest. Compounded semaglutide and tirzepatide remain available in 2026 — but the landscape looks very different from a year ago.

Here's a clear-eyed look at what changed, what stayed the same, and what you need to know before choosing a provider.

The Shortage Timeline: How We Got Here

What "Clinically Significant Difference" Actually Means

This is the regulatory concept keeping compounding alive post-shortage. Under federal law, a compounding pharmacy can produce a medication that is "essentially a copy" of a commercially available drug only during a shortage. Once the shortage ends, they need a different legal basis.

The pathway that most compliant compounders are using: creating formulations with a clinically significant difference from the branded version. In practice, this usually means adding an ingredient (like vitamin B12, L-carnitine, or NAD+), using a different concentration, or offering a different delivery method (sublingual drops, troches, oral dissolving tablets).

The FDA has not published a definitive list of what qualifies. This ambiguity has created a market where some providers operate with clear legal counsel and transparent formulations, while others push boundaries. Choosing a provider with a clean regulatory record matters more than ever.

What Actually Changed for Patients in 2026

1. Fewer Providers, Higher Average Quality

The post-shortage enforcement wave eliminated many low-quality operators. Providers still active in 2026 tend to have stronger pharmacy partnerships, LegitScript certification, and transparent formulation disclosure. The bar has gone up — which is good for patients, even if there are fewer options.

2. Prices Have Compressed

Competition from Eli Lilly's direct-to-consumer pricing ($399/month for Zepbound through LillyDirect) and Novo Nordisk's NovoCare self-pay programs has forced compounders to sharpen pricing. Most quality compounded semaglutide programs now fall between $146 and $299 per month, down from $200–$450 a year ago.

3. Formulation Diversity Has Increased

To maintain the "clinically significant difference" basis, compounders have expanded beyond simple injectable semaglutide. You'll now find semaglutide + B12, semaglutide + NAD+, sublingual tablets, troches, and oral dissolving formats. Each has different bioavailability profiles — injectable remains the gold standard for consistent absorption.

4. Brand-Name Alternatives Are More Accessible

A year ago, brand-name GLP-1s were largely out of reach for cash-pay patients. Now, self-pay programs from manufacturers and providers offering brand-name prescriptions at $349–$499/month have created a viable middle ground between compounded ($150–$300) and full list price ($1,000+).

How to Choose a Compounding Provider in 2026

The post-shortage landscape rewards due diligence. Before choosing a provider, verify these five things:

Pharmacy type disclosure. Ask whether the pharmacy is 503A (patient-specific prescriptions, state-regulated) or 503B (outsourcing facility, FDA-registered, cGMP standards). 503B facilities provide an additional layer of quality oversight.

Formulation transparency. The provider should clearly state what's in your vial — active ingredient, concentration, additives, and the "significant difference" basis for their formulation.

LegitScript certification. This third-party verification screens telehealth pharmacies for legitimate business practices. Not all good providers have it, but it's a strong signal when they do.

Regulatory record. Check whether the provider has received FDA warning letters. You can search the FDA's warning letter database directly. A warning letter doesn't automatically mean the product is unsafe, but it means the company has made claims the FDA considers misleading.

Pricing transparency. The total cost should be clear before you complete a consultation — including medication, shipping, consultation fees, and any membership or subscription charges.

Providers With Clean Records in 2026

These providers have maintained compliant operations through the post-shortage transition, with transparent pricing and no unresolved FDA actions:

The Bottom Line

Compounded GLP-1 medications didn't disappear when the shortage ended — but the easy, unregulated era did. The providers that survived the 2025 enforcement wave are generally the ones that invested in compliance, quality pharmacy partnerships, and transparent operations.

For patients, this means more work upfront (verifying providers, understanding formulations) but a safer market overall. If you're considering compounded GLP-1 medication in 2026, start with providers that disclose their pharmacy type, formulation details, and have a clean regulatory record.